PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.44 - 1.45
1.18 - 2.36
89.1K / 1.73M (Avg.)
-18.12 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
29.47%
Positive revenue growth while 1097.HK is negative. John Neff might see a notable competitive edge here.
12.43%
Gross profit growth under 50% of 1097.HK's 78.96%. Michael Burry would be concerned about a severe competitive disadvantage.
No Data
No Data available this quarter, please select a different quarter.
-10.38%
Negative operating income growth while 1097.HK is at 124.91%. Joel Greenblatt would press for urgent turnaround measures.
-275.35%
Negative net income growth while 1097.HK stands at 117.09%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-274.29%
Negative EPS growth while 1097.HK is at 117.14%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-274.29%
Negative diluted EPS growth while 1097.HK is at 117.20%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.21%
Share reduction while 1097.HK is at 0.54%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while 1097.HK stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
13.10%
OCF growth under 50% of 1097.HK's 18470.24%. Michael Burry might suspect questionable revenue recognition or rising costs.
21.15%
FCF growth under 50% of 1097.HK's 337.62%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-99.43%
Negative 10Y revenue/share CAGR while 1097.HK stands at 41.75%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-99.52%
Negative 5Y CAGR while 1097.HK stands at 46.81%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
1840.00%
3Y revenue/share CAGR above 1.5x 1097.HK's 52.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-224.03%
Negative 10Y OCF/share CAGR while 1097.HK stands at 16.44%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-150.91%
Negative 5Y OCF/share CAGR while 1097.HK is at 103.75%. Joel Greenblatt would question the firm’s operational model or cost structure.
-156.03%
Negative 3Y OCF/share CAGR while 1097.HK stands at 246.84%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-197.87%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-124.60%
Negative 5Y net income/share CAGR while 1097.HK is 157.45%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-106.58%
Negative 3Y CAGR while 1097.HK is 123.66%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
160.62%
3Y equity/share CAGR above 1.5x 1097.HK's 12.94%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-99.99%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-99.99%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.26%
We have a declining book value while 1097.HK shows 1.11%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.